Full text is available at the source.
Abstract
A total of 2,994 women with type 2 diabetes exposed to glucagon-like peptide-1 receptor agonists in early pregnancy showed no increased risk of malformations.
- Animal studies suggest potential risks of fetal loss, malformations, and adverse fetal growth associated with GLP-1RA exposure.
- Three cohort studies and one prospective study found no evidence of increased malformations in pregnancies exposed to GLP-1RAs compared to unexposed ones.
- Observational data from 168 pregnancies exposed to GLP-1RAs indicate no increased risk of miscarriage or adverse fetal growth.
- Women with type 2 diabetes are recommended to use contraception and discontinue GLP-1RAs two months prior to planned pregnancy.
- Existing human evidence does not support terminating a pregnancy if a woman with type 2 diabetes becomes unintentionally pregnant while using GLP-1RAs.
Simplified